Matinas BioPharma to be Acquired by New Mountain Capital
Ticker: MTNB · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, going-private, private-equity
TL;DR
Matinas BioPharma is going private, being bought by New Mountain Capital.
AI Summary
Matinas BioPharma Holdings, Inc. announced on August 27, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of the private equity firm New Mountain Capital. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition will result in Matinas BioPharma becoming a privately held company.
Why It Matters
This acquisition signifies a shift for Matinas BioPharma from a publicly traded entity to private ownership under New Mountain Capital, potentially impacting its strategic direction and access to capital.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Company being acquired
- New Mountain Capital (company) — Acquiring private equity firm
- August 27, 2024 (date) — Date of definitive agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring Matinas BioPharma Holdings, Inc.?
An affiliate of the private equity firm New Mountain Capital is acquiring Matinas BioPharma Holdings, Inc.
What is the expected closing timeframe for the acquisition?
The acquisition is expected to close in the fourth quarter of 2024.
What is the significance of this transaction for Matinas BioPharma?
The transaction will result in Matinas BioPharma becoming a privately held company.
What conditions must be met for the acquisition to close?
The acquisition is subject to customary closing conditions.
On what date was the definitive agreement for the acquisition announced?
The definitive agreement was announced on August 27, 2024.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-27 21:39:57
Key Financial Figures
- $0.0001 — f its shares of common stock, par value $0.0001 per share (the " Common Stock "), had b
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-034098.txt ( ) — 204KB
- mtnb-20240827.xsd (EX-101.SCH) — 3KB
- mtnb-20240827_lab.xml (EX-101.LAB) — 33KB
- mtnb-20240827_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: August 27, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-